These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

719 related items for PubMed ID: 2156986

  • 1. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA, Heyman JS, Sheldon RJ, Koslo RJ, Porreca F.
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [Abstract] [Full Text] [Related]

  • 2. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH, Sumpter TL, Burke TF, Husbands SM, Lewis JW, Woods JH, Traynor JR.
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [Abstract] [Full Text] [Related]

  • 3. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice.
    Roerig SC, Fujimoto JM.
    J Pharmacol Exp Ther; 1989 Jun; 249(3):762-8. PubMed ID: 2567350
    [Abstract] [Full Text] [Related]

  • 4. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
    Tseng LF, Collins KA.
    J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
    [Abstract] [Full Text] [Related]

  • 5. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse.
    Porreca F, Mosberg HI, Hurst R, Hruby VJ, Burks TF.
    J Pharmacol Exp Ther; 1984 Aug; 230(2):341-8. PubMed ID: 6086883
    [Abstract] [Full Text] [Related]

  • 6. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
    Millan MJ, Członkowski A, Lipkowski A, Herz A.
    J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
    [Abstract] [Full Text] [Related]

  • 7. Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
    Zimmerman DM, Leander JD, Reel JK, Hynes MD.
    J Pharmacol Exp Ther; 1987 May; 241(2):374-8. PubMed ID: 3033213
    [Abstract] [Full Text] [Related]

  • 8. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
    Mizoguchi H, Spaulding A, Leitermann R, Wu HE, Nagase H, Tseng LF.
    J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
    [Abstract] [Full Text] [Related]

  • 9. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK, Meert TF.
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [Abstract] [Full Text] [Related]

  • 10. Kappa opioids in rhesus monkeys. II. Analysis of the antagonistic actions of quadazocine and beta-funaltrexamine.
    Dykstra LA, Gmerek DE, Winger G, Woods JH.
    J Pharmacol Exp Ther; 1987 Aug; 242(2):421-7. PubMed ID: 3302207
    [Abstract] [Full Text] [Related]

  • 11. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
    Mjanger E, Yaksh TL.
    J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
    [Abstract] [Full Text] [Related]

  • 12. Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation.
    Shook JE, Lemcke PK, Gehrig CA, Hruby VJ, Burks TF.
    J Pharmacol Exp Ther; 1989 Apr; 249(1):83-90. PubMed ID: 2540324
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological characterization of nalorphine, a kappa 3 analgesic.
    Paul D, Pick CG, Tive LA, Pasternak GW.
    J Pharmacol Exp Ther; 1991 Apr; 257(1):1-7. PubMed ID: 1850462
    [Abstract] [Full Text] [Related]

  • 14. Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output.
    Craft RM, Dykstra LA.
    J Pharmacol Exp Ther; 1992 Jan; 260(1):327-33. PubMed ID: 1309876
    [Abstract] [Full Text] [Related]

  • 15. Intrathecal beta-funaltrexamine antagonizes intracerebroventricular beta-endorphin- but not morphine-induced analgesia in mice.
    Suh HH, Tseng LF.
    J Pharmacol Exp Ther; 1988 May; 245(2):587-93. PubMed ID: 2966856
    [Abstract] [Full Text] [Related]

  • 16. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice.
    Takemori AE, Portoghese PS.
    J Pharmacol Exp Ther; 1987 Oct; 243(1):91-4. PubMed ID: 2822908
    [Abstract] [Full Text] [Related]

  • 17. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL, Bartlett JL, Ananthan S, Bilsky EJ.
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [Abstract] [Full Text] [Related]

  • 18. Naloxone benzoylhydrazone (NalBzoH) analgesia.
    Paul D, Levison JA, Howard DH, Pick CG, Hahn EF, Pasternak GW.
    J Pharmacol Exp Ther; 1990 Nov; 255(2):769-74. PubMed ID: 2173757
    [Abstract] [Full Text] [Related]

  • 19. Nalbuphine, a mixed kappa 1 and kappa 3 analgesic in mice.
    Pick CG, Paul D, Pasternak GW.
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1044-50. PubMed ID: 1326621
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
    Gistrak MA, Paul D, Hahn EF, Pasternak GW.
    J Pharmacol Exp Ther; 1989 Nov; 251(2):469-76. PubMed ID: 2553921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.